Tags

Type your tag names separated by a space and hit enter

Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants.

Abstract

PURPOSE

To evaluate the impact of selenium chemoprevention (200 microg/day) on hospitalizations in HIV-positive individuals.

METHOD

Data were obtained from 186 HIV+ men and women participating in a randomized, double-blind, placebo-controlled selenium clinical trial (1998-2000). Supplements were dispensed monthly, and clinical evaluations were conducted every 6 months. Inpatient hospitalizations, hospitalization costs, and rates of hospitalization were determined 2 years before and during the trial.

RESULTS

At enrollment, no significant differences in CD4 cell counts or viral burden were observed between the two study arms. Fewer placebo-treated participants were using antiretrovirals (p <.05). The total number of hospitalizations declined from 157 before the trial to 103 during the 2 year study. A marked decrease in total admission rates (RR = 0.38; p =.002) and percent of hospitalizations due to infection/100 patients for those receiving selenium was observed (p =.01). As a result, the cost for hospitalization decreased 58% in the selenium group, compared to a 30% decrease in the placebo group (p =.001). In the final analyses, selenium therapy continued to be a significant independent factor associated with lower risk of hospitalization (p =.001).

CONCLUSION

Selenium supplementation appears to be a beneficial adjuvant treatment to decrease hospitalizations as well as the cost of caring for HIV-1-infected patients.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Disease Prevention, Department of Psychiatry and Behavioral Sciences, Miami, Florida 33136, USA.

    , , , , , ,

    Source

    HIV clinical trials 3:6 pg 483-91

    MeSH

    Adult
    Antiretroviral Therapy, Highly Active
    CD4 Lymphocyte Count
    Chemotherapy, Adjuvant
    Dietary Supplements
    Double-Blind Method
    Female
    Florida
    HIV Infections
    Hospital Costs
    Hospitalization
    Humans
    Male
    Middle Aged
    Selenium
    Treatment Outcome
    Viral Load

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    12501132

    Citation

    Burbano, Ximena, et al. "Impact of a Selenium Chemoprevention Clinical Trial On Hospital Admissions of HIV-infected Participants." HIV Clinical Trials, vol. 3, no. 6, 2002, pp. 483-91.
    Burbano X, Miguez-Burbano MJ, McCollister K, et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. HIV Clin Trials. 2002;3(6):483-91.
    Burbano, X., Miguez-Burbano, M. J., McCollister, K., Zhang, G., Rodriguez, A., Ruiz, P., ... Shor-Posner, G. (2002). Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. HIV Clinical Trials, 3(6), pp. 483-91.
    Burbano X, et al. Impact of a Selenium Chemoprevention Clinical Trial On Hospital Admissions of HIV-infected Participants. HIV Clin Trials. 2002;3(6):483-91. PubMed PMID: 12501132.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. AU - Burbano,Ximena, AU - Miguez-Burbano,Maria Jose, AU - McCollister,Kathryn, AU - Zhang,Guoyan, AU - Rodriguez,Allan, AU - Ruiz,Phillip, AU - Lecusay,Robert, AU - Shor-Posner,Gail, PY - 2002/12/26/pubmed PY - 2003/2/14/medline PY - 2002/12/26/entrez SP - 483 EP - 91 JF - HIV clinical trials JO - HIV Clin Trials VL - 3 IS - 6 N2 - PURPOSE: To evaluate the impact of selenium chemoprevention (200 microg/day) on hospitalizations in HIV-positive individuals. METHOD: Data were obtained from 186 HIV+ men and women participating in a randomized, double-blind, placebo-controlled selenium clinical trial (1998-2000). Supplements were dispensed monthly, and clinical evaluations were conducted every 6 months. Inpatient hospitalizations, hospitalization costs, and rates of hospitalization were determined 2 years before and during the trial. RESULTS: At enrollment, no significant differences in CD4 cell counts or viral burden were observed between the two study arms. Fewer placebo-treated participants were using antiretrovirals (p <.05). The total number of hospitalizations declined from 157 before the trial to 103 during the 2 year study. A marked decrease in total admission rates (RR = 0.38; p =.002) and percent of hospitalizations due to infection/100 patients for those receiving selenium was observed (p =.01). As a result, the cost for hospitalization decreased 58% in the selenium group, compared to a 30% decrease in the placebo group (p =.001). In the final analyses, selenium therapy continued to be a significant independent factor associated with lower risk of hospitalization (p =.001). CONCLUSION: Selenium supplementation appears to be a beneficial adjuvant treatment to decrease hospitalizations as well as the cost of caring for HIV-1-infected patients. SN - 1528-4336 UR - https://www.unboundmedicine.com/medline/citation/12501132/full_citation L2 - http://www.tandfonline.com/doi/full/10.1310/A7LC-7C9V-EWKF-2Y0H DB - PRIME DP - Unbound Medicine ER -